This page shows the latest Freeline news and features for those working in and with pharma, biotech and healthcare.
This will help frees up its portfolio for new investments. Since 31 March 2019, Syncona has invested £64.1min to its portfolio companies, including gene therapy companies Freeline and Gyroscope and
Quell is the tenth life science company founded by Syncona, with other UK-based cell and gene therapy companies on its roster including Gyroscope and Freeline.
These include Freeline, which last year raised £88m to accelerate haemophilia gene therapy, and Gyroscope, which earlier this month dosed its first patient with its gene therapy for dry AMD, and
Also in the hunt is UK-German biotech Freeline, which reported preliminary data from a phase 1/2 trial of its FLT180a candidate at last year’s American Society of Haematology
Another emerging competitor is UK start-up Freeline Therapeutics, which has just raised around $112m to help advance its haemophilia B gene therapy candidate which has also shown early promise in
Another emerging competitor is UK start-up Freeline Therapeutics, which has just raised around $112m to help advance its haemophilia B gene therapy candidate which has also shown early promise in
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
She joins from Gyroscope Therapeutics to take up CEO role. London, UK-based gene therapy-focused biopharmaceutical company Freeline Therapeutics has appointed Anne Prener as its new chief executive officer. ... Frener said: “I am excited to be joining
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....